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The burden of diarrheal diseases is very high, accounting for 1.7 
to 5 billion cases per year worldwide. Typhoid fever (TF) and 
cholera are potentially life-threatening infectious diseases, and 
are mainly transmitted through the consumption of food, drink 
or water that have been contaminated by the feces or urine of 
subjects excreting the pathogen. TF is mainly caused by Salmo-
nella typhi, whereas cholera is caused by intestinal infection by 
the toxin-producing bacterium Vibrio cholerae. These diseases 
typically affect low- and middle-income countries where housing 
is overcrowded and water and sanitation are poor, or where con-
flicts or natural disasters have led to the collapse of the water, 
sanitation and healthcare systems. Mortality is higher in children 
under 5 years of age. Regarding their geographical distribution, 
TF has a high incidence in sub-Saharan Africa, India and south-
east Asia, while cholera has a high incidence in a few African 
countries, particularly in the Horn of Africa and the Arabian Pen-
insula.
In the fight against these diseases, preventive measures are fun-
damental.
With modern air travel, transmissible diseases can spread 
across continents and oceans in a few days, constituting a threat 
to global public health. Nowadays, people travel for many rea-
sons, such as tourism and business. Several surveys have shown 
that a high proportion of travelers lack adequate information 
on safety issues, such as timely vaccination and prophylactic 
medications. The main objective of this overview is to provide 
information to help European travelers to stay healthy while 
abroad, and thus also to reduce the potential importation of 
these diseases and their consequent implications for public 
health and society.
The preventive measures to be implemented in the case of travel to 
countries where these diseases are still endemic are well known: 
the adoption of safe practices and vaccinations. It is important to 
stress that an effective preventive strategy should be based both on 
vaccinations and on hygiene travel guidelines.
Furthermore, the emergence of multidrug-resistant strains is 
becoming a serious problem in the clinical treatment of these dis-
eases. For this reason, vaccination is the main solution. 
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Introduction
The burden of diarrheal disease is very high, account-
ing for 1.7 to 5 billion cases per year worldwide. Spe-
cifically, diarrheal diseases are associated with an esti-
mated 1.3 million deaths ann-ually, with most occurring 
in resource-limited countries. Very young children are 
the most vulnerable, the incidence of severe gastroen-
teritis being highest in the first 2 years of life. Indeed, 
up to 25% of deaths in young children in Africa and 
south-east Asia are attributable to acute gastroenteri-
tis. In these geographical areas, total mortality has de-
clined in recent decades, owing to the increased use of 
oral rehydration therapy, improved nutrition, increased 
breastfeeding, better supplemental feeding, female edu-
cation, immunization and improvements in hygiene and 
sanitation. Nevertheless, morbidity due to diarrhea has 
not declined in the same manner. Indeed, in low-income 
countries, children under three years old experience, on 
average, three episodes of diarrhea every year. Although 
the burden is greatest in low-income populations with 
poor access to safe water, sanitation and urgent medical 
care, acute infectious diarrhea is also a common cause of 
outpatient visits and hospital admissions in high-income 
regions, and is a major health problem globally [1].
Diarrhea is caused by a wide range of etiological agents, 
including viruses, bacteria and parasites. Among the 
etiological agents responsible for diarrheal diseases are 
Salmonella Typhi (S. typhi), Salmonella Paratyphi (S. 
paratyphi) and Vibrio Cholerae. In this overview, the 
burden of typhoid and paratyphoid fever and cholera is 
described in order to provide updated information for 
European travelers to endemic areas and to identify the 
best preventive strategies.
Typhoid and paratyphoid fever
Typhoid fever (TF), also known as enteric fever, is a 
potentially life-threatening multi-systemic illness. It is 
mainly caused by Salmonella enterica, subspecies en-
terica serovar typhi, and to a lesser extent by serovars 
paratyphi A, B, and C, which are members of the fam-
ily of Enterobacteriaceae [2]. The genus Salmonella is 
divided into serovars on the basis of surface antigens: O 
antigen, based on the lipopolysaccharide (LPS) compo-
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nent; and H antigen, based on flagellar proteins. More-
over, pathogenic strains of S. typhi and S. paratyphi C 
present a Vi antigen polysaccharide component [3]. 
Clinical features
S. typhi is restricted to human hosts, and chronic carriers 
constitute the reservoir of infection.
The disease is mainly transmitted through the consump-
tion of food, drink or water that have been contaminated 
by the feces or urine of subjects excreting bacteria (sick 
or convalescent people or chronic asymptomatic car-
riers). After S. typhi has been ingested, it reaches the 
intestinal epithelium, where it colonizes macrophages 
and dendritic cells in the lamina propria; however, these 
fail to destroy the bacterium [4]. Subsequently, bacte-
ria invade the bloodstream, multiply and spread to the 
lymph nodes, spleen and liver, causing multi-systemic 
disease [5]. The main manifestations of the disease are 
fever, which can reach 38°-40°C, and abdominal symp-
toms (such as diarrhea or constipation). Nonspecific 
symptoms, such as weakness, anorexia, headache and 
dizziness, may precede the fever. Moreover, rose-col-
ored spots may appear on the trunk, and patients may 
also experience neuropsychiatric manifestations, hepa-
tomegaly and splenomegaly. The most severe complica-
tions are gastrointestinal bleeding, intestinal perforation 
and typhoid encephalopathy, which occur in 10-15% of 
patients, generally in the third and fourth weeks of infec-
tion [6, 7]. The duration of infection is a major deter-
minant of the risk of severe complications, and a delay 
in administering appropriate antibiotic treatment may 
have serious consequences. Isolation of S. typhi from 
blood is the most common method of diagnosis, though 
the bacterium can also be isolated from bone marrow, 
feces and duodenal fluid. Blood culture displays subop-
timal sensitivity, generally being positive in only about 
50% of cases. It also has several limitations, including 
the volume of blood needed, the need for prompt trans-
port to the laboratory, interference due to prior antibiotic 
use, limited laboratory expertise and equipment, and ex-
pense [8]. Bone marrow culture increases the diagnostic 
yield to approximately 80% of cases. Stool culture is not 
usually positive during the earliest phase of the disease 
[9]. Multiple cultures increase sensitivity and may be re-
quired in order to reach a diagnosis. Although the Widal 
test (based on the detection of agglutinating antibodies 
to ‘O’ and ‘H’ antigens) is unreliable (may give false-
positive or false-negative results), it is widely used in de-
veloping countries because of its low cost. Newer sero-
logic assays for S. typhi infection are occasionally used 
in outbreak situations, and are somewhat more sensitive 
and specific than the Widal test [2]. Early diagnosis and 
the prompt institution of appropriate antibiotic treatment 
are essential for the optimal management of TF, espe-
cially in children. S. paratyphi causes paratyphoid fever. 
S. paratyphi is thought to cause milder disease than S. 
typhi, with symptoms being predominantly gastrointes-
tinal [10]. While this is probably true of S. paratyphi B 
infection, there are insufficient data to draw conclusions 
regarding S. paratyphi A [11]. 
Ciprofloxacin is commonly used as an empiric treatment, 
as fluoroquinolones are recommended. However, as 
fluoroquinolone-resistant or multidrug-resistant strains 
are spreading, third-generation cephalosporins are used 
when the possibility of resistance is high [6, 12].
Epidemiology
TF is one of the main causes of enteric disease world-
wide [13]. The incidence of TF (overall population) is 
reported in Figure 1. Recent estimates of the global in-
cidence of typhoid and paratyphoid fevers in 2017 in-
dicate 14.3 million people affected (76.3% caused by 
S. typhi) [14], a 44.6% decline from the 25.9 million in 
1990 [5, 8, 15, 16]. 
The distribution of the disease differs widely throughout 
the world (Fig. 1). In geographical areas with a high inci-
dence, the main risk factors are inadequate drinking wa-
ter and inadequate sanitation; indeed, low- and middle-
income countries are mainly affected, owing to the lack 
of clean water and of proper sanitation. Moreover, other 
risk factors are: high population density, unsanitary liv-
ing conditions, poor hygiene, low socio-economic sta-
tus, and recent contact with a patient affected by TF [17]. 
In 2014, the World Health Organization (WHO) attrib-
uted 502,000 deaths to inadequate drinking water and 
280,000 to inadequate sanitation [18]. TF has a heavy 
burden in Asia, with an overall incidence of 170.8 cases 
per 100,000 people per year, though this estimate var-
ies across the continent [14]. Specifically, Buckle et al. 
estimated an annual incidence rate of 394.2 per 100,000 
in southern Asia. With regard to Africa, the incidence 
is estimated to be 724.6 cases per 100,000 people per 
year; however, it is probably underestimated, owing to 
the lack of information and surveillance systems in the 
continent [14]. Moreover, Africa suffers many cases of 
invasive non-typhoid salmonellosis, which are addition-
al confounding factors in estimating the TF burden [17]. 
TF also affects countries in Latin America, the Carib-
bean and Oceania, although to a lesser extent, with a 
median incidence rate of 22.3 cases per 100,000 people 
per year [5]. 
In 2014, Mogasale V et al. studied the incidence of TF 
in various parts of the world, showing that it was con-
siderably higher in low- and middle-income countries 
(risk-adjusted and corrected for blood culture sensitiv-
ity) (Fig. 1) [19].
A 2017 study by Antillón et al. found that the age-group 
most commonly affected by the disease is in the range 
between 2 and 14 years. Specifically, incidence peaks in 
the 2-4 years age-group, while it is lower in children < 2 
years of age and adults. It must be stressed that children, 
even when properly treated, have a high mortality rate. 
These authors estimated that the expected number of TF 
cases per year is 17.8 million across all low-income and 
middle-income countries. According to their analysis, 
almost 40% of all cases occur in sub-Saharan Africa 
(7.2 million), although the uncertainty of their estimates 
is considerable. Figure 2 reports the incidence (per 
100,000 person-years) in the Global Burden of Disease 
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Fig. 1. Typhoid incidence in low- and middle-income countries (risk-adjusted and corrected for blood culture sensitivity), adapted from 
Mogasale et al. [19]. Colors indicate different incidence values, with darker shades corresponding to higher incidence.
Fig. 2. Incidence in the Global Burden of Disease regions and sub-regions made up of low- and middle-income countries. The incidence is 
per 100,000 person-years. Adapted from Antillón et al. [20].
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regions and sub-regions made up of low- and middle-
income countries [20].
In developed countries, the incidence rate per 100,000 
per year varies from < 0.1 to 0.3, and the disease mainly 
affects people who travel to endemic areas located in 
low- and middle-income countries [15].
The median TF mortality rate varies from region to re-
gion: high-income countries such as North America, Eu-
rope, Australia and New Zealand register less than 0.1 
deaths per 100,000 people per year, while the mortality 
rate is higher in Sub-Saharan Africa (7.2) and Southern 
Asia (3.9) [15].
S. paratyphi A has been found to be responsible for a 
considerable, and increasing, proportion of cases of en-
teric fever in some Asian regions [8].
A very recent systematic review by Marchello et al. re-
ports the incidence of blood culture-confirmed TF with-
out restrictions on age, country, language or time. The 
authors identified Africa and Asia as regions with high 
TF incidence, with a peak in children younger than 15 
years old (particularly between 2 and 4 years old). These 
results confirm the global incidence trend of new cases 
of TF [21].
The impact of S. typhi and S. paratyphi disease is prob-
ably underestimated, owing to inadequate surveillance 
systems in the most severely affected areas, the low sen-
sitivity of diagnostic tools, and healthcare inequalities 
resulting in scant health-seeking behavior among popu-
lations at the highest risk [22].
Vaccination
Despite major efforts to prevent and treat cases of enteric 
fever, millions of new infections of typhoid fever occur 
in many areas where sanitation is poor and food and wa-
ter supplies are unsafe, frequently involving travelers to 
endemic areas [22]. 
In the fight against this plague, preventive measures are 
fundamental. Vaccination against typhoid is an effective 
preventive intervention, especially when coupled with 
hand-washing, the treatment of household water, and the 
provision of adequate sanitation [4]. 
Well-tolerated and effective vaccines are currently avail-
able. One of these is based on the use of live attenuated 
bacteria and is administered orally; the other is based on 
Vi capsular polysaccharide (Vi-PS), and is administered 
intramuscularly or subcutaneously [4]. 
Ty21a vaccine (Vivotif®)
A mutated strain of Salmonella (Ty21a) that reproduces 
the natural infection is contained in Ty21a vaccine (Vi-
votif®).
The Ty21a strain is a Ty2 mutant, with deficiency of 
the uridyl diphosphate-galactose enzyme (UDP-Gal) 
-4-epimerase. The deficiency of this enzyme prevents 
the conversion of UDP glucose to UDP galactose, one of 
the components of the lipopolysaccharide membrane of 
Salmonella. The absence of galactose UDP determines 
the formation of an LPS that does not contain O anti-
gen, which is the most important surface antigen. In this 
phase, the mutant strain is not immunogenic; however, 
since the Ty21a strain is fed by galactose, the bacterium 
becomes capable of generating UDP galactose by means 
of an alternative route, managing to express a complete 
and immunogenic LPS. Despite its immunogenic ca-
pacity, the mutant strain is not virulent, as the galactose 
is partially accumulated as galactose-1-phosphate and 
UDP-galactose, which induce bacterial lysis. S. typhi 
Ty21a is a stable mutant with no possibility of reversion 
either in vitro or in vivo. This particular strain causes 
an abortive infection, stimulating an immune response 
at the intestinal level and inducing both a humoral, cell-
mediated and antibody reaction [23, 24].
Therapeutic indications
Children aged over 5 years and adults can take the Ty21a 
vaccine orally. The pack contains 3 capsules, to be taken 
every other day, with cold or lukewarm water, at least an 
hour before meals. The protection starts between 7 and 
10 days after the third dose.
In countries where the risk of contracting the disease is 
high, vaccination is recommended every 3 years. Simi-
larly, on the basis of new summary of product charac-
teristics, those traveling to an endemic area should be 
vaccinated every 3 years [25]. The vaccination schedule 
must be completed at least one week before going to an 
endemic area.
Vivotif® may be administered concomitantly with yel-
low fever vaccine and oral polio vaccine. 
Immunogenicity, efficacy and safety
It has been shown that the vaccine stimulates a good lo-
cal production of IgA against the O antigen and that it 
induces good humoral and cell-mediated immunogenic-
ity against the O antigen in adult male subjects [26].
The immunogenicity of Ty21a was evaluated in 634 
Thai children, who underwent a three-dose vaccina-
tion schedule [27]. A seroconversion rate of 60% was 
found in 3-year-old children and of 91% in 6-year-old 
children (p <0.005); these percentages were higher than 
the seroconversion rates in unvaccinated children of the 
same age. The data showed that seroconversion rates in-
creased proportionally to the age of vaccinated children. 
Gilman et al. [28] studied 155 male adults vaccinated 
with Ty21a and observed good seroconversion rates of 
antibodies to the O antigen, resulting in disease protec-
tion.
In another controlled trial, 32,388 children were recruit-
ed in order to evaluate Ty21a vaccine (16,486 received 
the vaccine, 15,902 received oral placebo, and 25,625 
did not receive either) and it was reported that, out of 
92,675 doses administered, there were 49 cases of vom-
iting among vaccinees, versus 21 in the placebo group; 1 
case of fever after the vaccine and 3 cases in the control 
group, and finally 14 cases of abdominal pain in the vac-
cinated group, versus 2 cases in the placebo group [29]
Levine et al. described a randomized, placebo-con-
trolled field efficacy trial in Santiago (Area West); a to-
tal of 65,674 schoolchildren (aged 6-17 years) received 
three doses of vaccine. Volunteers were randomly as-
signed to two groups, one of which received the three 
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capsules within 48 hours (22,170 subjects), and the 
other within 21 days (21,598). Children who received 
placebo (21,906) served as the comparator group. The 
study demonstrated that the best protection was seen in 
the group that received all three doses of the vaccine in 
enteric-coated capsules within one week; prolonging the 
interval between doses to 21 days did not enhance ef-
ficacy [30].
Subsequently, a liquid formulation was commercialized 
after it had been shown to provide greater protection 
than enteric-coated capsules over three years of follow-
up in a randomized, placebo-controlled trial in Area 
South East and Area North, Santiago [31]. 
Surveillance in the Area West trial was continued for 
four additional years (i.e., total seven years of follow-up) 
and in the Area South East and Area North trial for two 
additional years (i.e., a total of five years of follow-up).
Over the course of a decade, it was possible to conduct 
separate large-scale trials to evaluate different immuni-
zation regimens and programs of Ty21a oral in vivo ty-
phoid vaccine. The results showed that over 3 years of 
follow-up in Santiago (Area West), there were 68 cases 
of bacteriologically confirmed typhoid fever in the pla-
cebo group and 23 cases in the short-interval vaccine 
group, yielding a point estimate of vaccine efficacy of 
67% (95% CI 47-79%; p < 0.00001). There were 34 cas-
es of confirmed typhoid fever in the long-interval group, 
providing a point estimate of vaccine efficacy of 49% 
(95% CI 24-66%; p = 0.0006).
In a field trial, the three-dose regimen of enteric-coat-
ed capsules taken on alternate days was shown to have 
a protective efficacy of 71% (95% CI 35-87%) during 
the first year after vaccination, 67% (95% CI 47-79%) 
over 3 years, and 62% (95% CI 48-73%) over 7 years 
of follow-up, which definitively supports the efficacy 
reported in the vaccine summary of product character-
istics [31].
Moreover, the data from the Area South East and Area 
North trial revealed that three doses of liquid formula-
tion conferred 77% (95% CI 60 ± 87%; p < 0.001) pro-
tection over three years and 79% (95% CI 65 ± 87%; 
p < 0.001) over five years of follow-up, showing the 
efficacy of three doses of the liquid formulation of 
Ty21a [31].
Other studies of vaccine immunogenicity, safety and 
tolerability have demonstrated the good profile of Vivo-
tif® [32-34]. 
Vi polysaccharide vaccine (Typhim Vi®)
Vi polysaccharide vaccine (Typhim Vi®) contains puri-
fied Vi capsular polysaccharide of Salmonella typhi (Ty 
2 strain). Immunity appears within 1-3 weeks after in-
jection and lasts around 3 years. A single dose of ViPS 
vaccine elicits high levels of serum IgG anti-Vi antibod-
ies. The persistence of anti-Vi antibodies depends on 
endemicity, with a trend towards greater persistence in 
endemic areas (documented up to 10 years in 83 children 
at levels equal to or above the serological correlate of 
protection of 1 µg/mL). In non-endemic areas, anti-Vi 
antibodies persist for 2 to 3 years [33].
Therapeutic indications
Typhim Vi® can be used in adults and children over 2 
years of age, administration being in a single dose of 0.5 
ml, with re-administration required every 2–3 years in 
subjects who remain at risk of typhoid fever. The com-
mon route of administration of this vaccine is intramus-
cular, although it may be given subcutaneously. Vacci-
nation should be carried out at least 2 weeks prior to 
potential exposure to S. typhi infection.
Typhim Vi® may be administered together with other 
common vaccines (yellow fever, diphtheria, tetanus, 
poliomyelitis, rabies prepared on Vero cells, meningitis 
A+C, hepatitis A and hepatitis B) during the same 
vaccination session [35].
Immunogenicity, efficacy and safety
A double-blind, randomized, controlled efficacy clinical 
trial was conducted in a highly endemic area of Nepal, 
in both pediatric and adult populations: 3,457 subjects 
received Typhim Vi®. The results indicated that the level 
of protection conferred by a single dose of the vaccine 
was 74% against blood culture-confirmed cases of TF 
throughout the 20 months of active surveillance, in com-
parison with the control group [36].
The seroconversion rate (defined as a 4-fold rise in an-
ti-Vi antibody levels) was recorded in 19 clinical trials 
involving a total 2,137 pediatric and adult subjects in en-
demic and non-endemic areas. In the adult population, 
the seroconversion rate ranged from 62.5% to 100% four 
weeks after a single injection, with a similar magnitude 
of anti-Vi immune response in non-endemic areas and 
endemic areas. Similar results were obtained in the pedi-
atric population.
During clinical development, more than 15,000 people 
received Typhim Vi® (first or second injection). The most 
common adverse reaction, in all age-groups, was injec-
tion site pain. In adults over 18 years of age, myalgia and 
fatigue were the most frequently reported systemic reac-
tions. In children and adolescents (from 2 to 17 years 
of age), myalgia and headache were the most frequently 
reported systemic reactions. Most adverse reactions ap-
peared within 3 days after vaccination and most resolved 
spontaneously within 1 to 3 days after onset [33, 37].
Cholera
Cholera is a rapidly-dehydrating diarrheal disease caused 
by intestinal infection by the toxin-producing bacterium 
Vibrio cholerae.
Vibrio cholerae strains are classified into serogroups 
on the basis of the structure of their cell surface lipo-
polysaccharides. Of the over 200 known serogroups of 
Vibrio cholerae, distinguished by the polysaccharides of 
the somatic (O) antigen, only the O1 and O139 serovars 
can produce the cholera toxin and cause pandemic dis-
ease [38]. There is no proven cross-protection between 
O1 and O139. On the basis of a number of phenotypic 
differences, including their susceptibility to polymyxin 
B and phage infection [39], the O1 serotype is further 
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classified into 2 biotypes, El Tor and classical O1. Both 
of these biotypes can be further classified into 2 cross-
reacting serovars, Ogawa and Inaba [40]. El Tor persists 
for a longer time in the environment and is associated 
with a higher rate of asymptomatic cases. The classical 
strains are believed to have been responsible for the six 
previous cholera pandemics in modern history, the first 
of which started in 1817. The El Tor biotype is respon-
sible for the longest and most severe seventh pandemic, 
which started in 1961 and continues today [41]. In 1992, 
a genetic derivative of the El Tor biotype, termed Vib-
rio cholerae O139 Bengal, caused extensive epidemics 
of cholera in India and Bangladesh and subsequently in 
other parts of south Asia [41]. The spread of the O139 
serogroup is restricted to Asia and over the years its inci-
dence has decreased following the appearance of a new 
El Tor strain in 1994  [42]. This serogroup switch has 
occurred several times over the past decade in cholera-
endemic regions, suggesting that acquired immunity 
plays an important role in the emergence of specific 
serogroups. Moreover, the rapid evolution and genetic 
rearrangement of O1 and O139 strains contribute to the 
persistence and re-emergence of this disease.
In recent years, new pathogenic variants of Vibrio choler-
ae have emerged as the genetic backbone of El Tor strains 
and the higher infectivity of classical strains, and are as-
sociated with increased ecological persistence, infectivity, 
disease severity, and dispersion worldwide [41, 43-47]. 
This strain is responsible for the epidemic on Hispan-
iola and may cause more severe episodes of cholera and 
higher death rates [12].
As Vibrio cholerae strains continue to adapt and evolve, 
understanding the underlying factors that contribute to 
their enhanced environmental persistence and increased 
transmission will be essential, in order to predict out-
breaks and establish preventive measures [48].
Cholera currently remains a serious public health prob-
lem in many countries, occurring as an endemic disease 
in some regions and causing major epidemics in some 
low/middle-income countries [49, 50].
Clinical features
Cholera displays an acute nature, leading to severe dehy-
dration within hours, and death if not treated adequately. 
Vibrios are gram-negative, highly motile and comma-
shaped, with a single polar flagellum. In affected indi-
viduals, Vibrio cholerae secretes a toxin (CT) that af-
fects the small intestine. The toxic action of CT depends 
on a specific receptor, the monosialosyl ganglioside 
GM1. The binding (B) subunit of the toxin attaches to 
GM1 and releases the active (A) subunit; this enters the 
host cell and activates the G protein, which stimulates 
adenylate cyclase [50]. This activation increases the 
outflow of chloride and bicarbonate from the cell and 
reduces sodium influx, causing water molecules to flow 
into the lumen of the gut. The consequent net fluid loss 
causes watery diarrhea and rapid dehydration, which, if 
untreated, can lead to hypotonic shock and death within 
12 hours of the first symptoms [38, 49, 51].
After an incubation period of approximately 18 h to 5 
days, the illness typically starts suddenly with passage 
of watery stools and vomiting. Systemic manifestations, 
such as fever, are absent unless there is a co-infection. 
Depending on the severity of dehydration, the patient 
may be thirsty and irritable and, in later stages, display 
lethargy, a rapid radial pulse, loss of skin turgor, dimin-
ished urine output, low blood pressure, rapid breathing 
and sunken eyes. When severely dehydrated, the patient 
may progress to hypovolemic shock. Complications of 
cholera include electrolyte imbalance, including hy-
pokalemia, hyponatremia, hypocalcemia and acidosis. 
Children can develop hypoglycemia due to depleted he-
patic glycogen reserves and insufficient gluconeogene-
sis, which may cause seizures [52]. Other complications 
include various manifestations of diminished perfusion 
of end organs, including acute renal failure, stroke and, 
in pregnant patients, miscarriage, premature delivery 
and stillbirth [12].
Susceptibility to infection by Vibrio cholerae depends 
both on adaptive immune responses, induced by previ-
ous infection or vaccination, and on innate host factors. 
A low gastric acid level has been associated with more 
severe cholera disease. The immune response in indi-
viduals with cholera is directed primarily against bacte-
rial surface molecules and against cholera toxin. The re-
sponse includes intestinal-mucosal secretory IgA (SIgA) 
and serum IgA, IgG, vibriocidal antibodies, antibody-
secreting cells, T cells and, of special importance for 
long-term protection, memory B cells and T cells [40].
Intriguingly, not all individuals infected with pathogenic 
Vibrio cholerae exhibit symptoms of cholera, and several 
host factors appear to impact on immunity to the disease. 
Both retinol deficiency and blood type O have been associ-
ated with an increased susceptibility to infection [53-56]. 
Regardless of blood type, higher transmission rates of 
cholera are observed between first-degree relatives than 
between less closely related contacts living in the same 
household, indicating that additional genetic factors play 
a role in the susceptibility to cholera [55].
Laboratory tests are not essential for the diagnosis of 
cholera, as the clinical picture of acute, non-bloody, 
profuse, watery diarrhea quickly leading to dehydration 
does not occur in many other scenarios [57]. Cholera is 
confirmed through culture of a stool specimen or rectal 
swab [12].
Treatment for cholera is relatively cheap and simple. 
Intravenous rehydration with Ringer’s lactate solution 
should be administered aggressively in order to restore 
the circulation. With adequate and timely rehydration, 
case-fatality rates (CFRs) are < 1%. The oral rehydration 
solution recommended by the WHO contains glucose as 
a source of carbohydrates, and has reduced osmolarity, 
which is associated with reduced stool output. Antiemet-
ics have no role, and might interfere with rehydration 
because of their sedating effects. Antibiotic treatment 
should be dictated by local antimicrobial susceptibility 
profiles. Azithromycin and ciprofloxacin are common-
ly used, although azithromycin has been shown to be 
more effective than ciprofloxacin in terms of shortened 
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duration of diarrhea, reduced stool volume, lower fre-
quency of vomiting and cessation of fecal excretion of 
vibrios [12, 40].
Epidemiology
The disease typically affects regions where housing is 
overcrowded and water and sanitation are poor, or where 
conflicts or natural disasters have led to the collapse of 
the water, sanitation and healthcare systems [58]. Access 
to safe water and improved sanitation facilities has elim-
inated the transmission of Vibrio cholerae, the causative 
agent, in high-income countries. However, the bacteria 
continue to afflict millions of people in less developed 
countries where adequate water and sanitation infra-
structure are not widely available [59].
Cholera epidemics are superimposed on the endemic 
disease in long cycles. These cycles are determined 
by waning levels of population immunity and periods 
of climate variability. When introduced into a cholera-
naive population, large-scale epidemics can occur, such 
as the ongoing Haitian epidemic that began in 2010. In 
epidemic settings where natural immunity is scant or ab-
sent, all age-groups are equally affected by the disease 
although mortality in children < 5 years is higher [59]. 
Epidemics occur unpredictably and are often associated 
with natural disasters and humanitarian emergencies that 
disrupt the supply of water and sanitation. [58].
The global burden of cholera is largely unknown, as 
the majority of cases are not reported [59]. The WHO 
estimates that only 5-10% of cases occurring annually 
are officially reported [60]. The main factors for this 
low reporting efficiency include the limited capacity of 
epidemiological surveillance systems and laboratories, 
and social, political and economic disincentives to re-
porting [61-63]. While safe drinking water and advanced 
sanitation systems have made the Global North cholera-
free for decades, the disease is still endemic in many 
regions, including Asia, Africa and the Americas, with 
1.3 billion people at risk, Sub-Saharan Africa being the 
worst affected [64].
As mentioned above, V. cholera originated in the Indi-
an subcontinent and caused six pandemics from 1827 
through 1923. The seventh pandemic has been ongoing 
since 1961, reaching South America and most of the 
Western Hemisphere in 1991 [65]. The WHO estimates 
2.8 million cases and 91,000 deaths annually. Recently, 
cholera has struck vulnerable communities, such as post-
earthquake Haiti (2010), Iraq and Yemen, where natu-
ral disasters, refugee movements, war and conflict in-
crease the risk of infection and outbreaks [66]. In 2017, 
the WHO gathered data on cholera from 71 countries 
worldwide: 34 countries reported a total of 1,227,391 
cases and 5,654 deaths (global case-fatality rate (CFR): 
0.5%) (Fig. 3), and 37 countries reported cases for the 
year [62].
Fig. 3. Countries reporting cholera cases in 2017 (Adapted from WHO, 2018) [67]. The colors indicate different values of incidence; a darker 
shade corresponds to a higher incidence.
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Yemen accounted for 84% of all suspected cases report-
ed and for 41% of cholera-attributed fatalities. Exclud-
ing cases related to Yemen, an increase of 45% in the 
number of cases and 33% in the number of deaths over 
the 2016 global totals was observed in Member States. 
The increase in 2017 was due largely to severe epidem-
ics in the Democratic Republic of the Congo (DRC), Ni-
geria, Somalia and South Sudan [68].
Since the last Communicable Disease Threats Report 
(CDTR), updated on 24 August 2018, the countries re-
porting the most cases have been Yemen (38,269 cases, 
63 deaths), Nigeria (7,966 cases, 224 deaths), the DRC 
(2,918 cases, 65 deaths), Niger (1,592 cases, 36 deaths) 
and Ethiopia (1103 cases). Since the last CDTR update, 
the WHO has declared the cholera outbreaks in Kenya 
and Uganda to be under control. Two countries have re-
cently reported new cholera outbreaks within their ter-
ritories: Algeria and Zimbabwe [68].
Natural disasters and epidemics
Epidemics occur unpredictably and are often associated 
with natural disasters and humanitarian emergencies that 
disrupt access to water and sanitation supplies. [57].
The WHO defines natural disasters as “catastrophic 
events with atmospheric, geologic and hydrologic ori-
gins”, including earthquakes, volcanic eruptions, storm 
surges, landslides, tsunamis, wildfires, floods and 
droughts [69, 70].
In humanitarian crises and emergencies, the lack of in-
frastructures often forces victims to seek refuge in tem-
porary accommodation, without adequate access to food, 
safe water and sanitation. Obviously, in such situations, 
public health surveillance systems may be suboptimal, 
disrupted or even non-existent, exacerbating the risk of 
transmission of communicable diseases [71]. Further-
more, the lack of electricity, laboratory equipment and 
supplies can make conventional testing for water-borne 
pathogens impossible [72].
Moreover, susceptibility to many diseases, including 
cholera, may be due to pre-existing health conditions, 
such as malnutrition, especially in infants and children. 
Indeed, a 2011 study [73] showed that cholera cases (or 
worse epidemics) are more likely to arise in malnour-
ished populations with limited food availability owing to 
famine, war or natural disasters [74]. A poor nutritional 
status may have many causes, such as a deficient macro/
micronutrient intake, malabsorption, metabolic distur-
bances and other health issues (e.g., HIV/AIDS); for ex-
ample, children with zinc and vitamin A deficiency are 
more susceptible to cholera [75].
Moreover, natural disasters affect the ecology of patho-
gens, mainly by increasing the risk of exposure to them, 
but also by facilitating their growth in aquatic environ-
ments, which are the main reservoir of pathogenic chol-
era bacteria [70, 76, 77]. In this regard, changes in the 
aquatic environment, such as plankton concentration, 
variations in salinity, temperature, pH, sediments and 
their re-suspension/transport and other physico-chemi-
cal factors, can promote the survival of the pathogen, 
especially in coastal zones [78].
In recent years, as a consequence of climate change 
and human activities (e.g., rapid urbanization, defores-
tation, etc.), the incidence of natural disasters has in-
creased  [69, 78, 79]. An estimate derived from the In-
ternational Disaster Database suggests that about 270 
million people each year are affected by natural disas-
ters [70, 80, 81].
However, not all disasters are followed by cholera epi-
demics; environmental conditions need to be conducive 
to the rapid growth of this bacterium, the pathogenic 
strains of which are susceptible to many factors, as seen 
above. Furthermore, societal structure, prevailing cli-
matic processes and the spatio-temporal seasonal vari-
ability of natural disasters play a very important role in 
predicting cholera outbreaks. Indeed, an already “frag-
ile” area is at greater risk of suffering an epidemic than 
a high-income area, which, by contrast, will be able to 
help the victims of a disaster promptly and can recover 
from it relatively quickly, before an outbreak can oc-
cur [70].
Vaccination
In order to prevent cholera, it is important to vaccinate 
both travelers to endemic areas and people who live in 
such areas. Currently, the available vaccine for European 
travelers is cholera inactivated vaccine (Dukoral®), that 
is administered orally.
Cholera inactivated vaccine (Dukoral®)
Cholera inactivated vaccine (Dukoral®) contains killed 
whole Vibrio cholerae O1 bacteria and the recombinant 
non-toxic B-subunit of the cholera toxin (CTB) [82].
Bacterial strains of both Inaba and Ogawa serovars and 
of El Tor and classical biotypes are included in the vac-
cine. Dukoral® is taken orally together with a bicarbonate 
buffer, which protects the antigens from the gastric acid. 
The vaccine acts by inducing antibodies against both the 
bacterial components and CTB. The intestinal antibacte-
rial antibodies prevent the bacteria from attaching to the 
intestinal wall, thereby impeding colonization by Vibrio 
cholerae O1. The intestinal anti-toxin antibodies prevent 
the cholera toxin from binding to the intestinal mucosal 
surface, thereby preventing the toxin-mediated diarrheal 
symptoms.
The heat-labile toxin (LT) of enterotoxigenic E. coli 
(ETEC) is structurally, functionally and immunologi-
cally similar to CTB. The two toxins cross-react immu-
nologically.
Therapeutic indications
Dukoral® is indicated for active immunization against 
disease caused by Vibrio cholerae serogroup O1 in 
adults and children from 2 years of age who will be vis-
iting endemic/epidemic areas. 
As reported in the summary of product characteristics, 
the use of Dukoral® should be determined on the basis of 
official recommendations, taking into consideration the 
variability of epidemiology and the risk of contracting 
the disease in different geographical areas and traveling 
conditions. However, Dukoral® should not replace stan-
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dard protective measures (such as washing hands, eating 
well-cooked foods, avoiding raw foods, eating only bev-
erages from sealed bottles, and if not boil them; remem-
ber: “boil it, cook it, peel it or forget it). 
The standard primary course of vaccination with Du-
koral® against cholera consists of 2 doses for adults and 
children from 6 years of age. Children from 2 to below 6 
years of age should receive 3 doses. Intervals of at least 
one week between doses are necessary. If more than 6 
weeks have elapsed between doses, the primary immu-
nization course should be re-started.
For continuous protection against cholera, a single 
booster dose is recommended within 2 years for adults 
and children from 6 years of age, and within 6 months 
for children aged 2 to 6 years. No clinical efficacy data 
have been generated on repeat booster dosing. However, 
immunological data and data on the duration of protec-
tion suggest that if up to 2 years have elapsed since the 
last vaccination in adults, and up to 6 months in children 
aged 2-6 years, a single booster dose should be given. If 
more than 2 years have elapsed since the last vaccina-
tion (more than 6 months in children aged 2-6 years) the 
primary course should be repeated.
Immunogenicity safety and tolerability
Safety and immunogenicity were studied in Bangladeshi 
children (n = 340) aged 6-18 months. The results showed 
that two doses of the vaccine were safe and induced an-
tibacterial (vibriocidal) antibody responses in 57% of 
the children and antitoxin responses in 85%. Immune 
responses were comparable after the administration of 
one and two doses. Administering the vaccines without 
buffer or in water did not affect vibriocidal responses. 
This study demonstrates that the vaccine is safe and 
immunogenic in children under 2 years of age and that 
simple interventions can enhance immune responses in 
young children [83].
In the Bangladesh Field Trial (1985) protective efficacy 
against cholera in adults and children aged ≥ 6 years was 
evaluated, and short-term protection was detected in 
85% of subjects [84]. 
In children aged 2-5 years in Mozambique, Dukoral® 
provided protection for 6 months [78% protection (CI 
39-92%)] [85]. Herd immunity was also registered in 
non-vaccinated individuals [86, 87].
Recently, Dukoral® was evaluated in a clinical trial: 
healthy volunteers (n = 21) and renal transplant recipi-
ents (n = 30) were vaccinated with the oral whole cell/
recombinant B subunit cholera vaccine Dukoral®. The 
vaccine was administered at the baseline and on day 14. 
The results showed that more than half of the transplant 
recipients seroconverted, and adverse events were mild 
to moderate and transient [88].
Several studies have investigated the cross-protection 
of Dukoral® against enterotoxigenic Escherichia co-
li  [84,  89, 90]. In particular, one study found that the 
protective efficacy against cholera was 85% and protec-
tion against the toxin of enterotoxigenic Escherichia coli 
reached 67% [90].
S. typhi and cholera: similarities  
and differences
Concerning similarities, TF and cholera are both trans-
mitted through the oro-fecal route. Owing to poor sani-
tary conditions and lack of safe drinking water, which 
are often associated with poverty and deprivation, de-
veloping countries are most severely affected by these 
diseases [91].
In the 19th and 20th centuries, oro-fecal transmissible 
diseases were endemic in many areas of the world, in-
cluding Europe and the Americas. After the widespread 
introduction of chlorination, sand filtration and other 
practical preventive methods of water sanification, the 
spread of oro-fecal diseases decreased drastically world-
wide. Today, the WHO is actively involved in reducing 
the transmission of diseases caused by critical health 
conditions, particularly in middle- and low-income 
countries.
The new WHO Guidelines on Sanitation and Health [92] 
summarize the evidence on the effectiveness of a range 
of sanitation interventions and provide a comprehensive 
framework for health-protecting sanitation; this covers 
policy and governance measures, the implementation of 
sanitation technologies, systems and behavioral inter-
ventions, and monitoring approaches. 
Critically, the guidelines detail the role of the health sec-
tor in identifying gaps in sanitation interventions, in or-
der to guide future research efforts and to improve and 
maximize the effectiveness of sanitation interventions 
on the health of the population (a WHO study in 2012 
calculated that for every US$ 1.00 invested in sanitation 
there was a return of US$ 5.50 in lower health costs, 
increased productivity, and fewer premature deaths). 
Indeed, the benefits of improved sanitation extend well 
beyond reducing the risk of diarrheal disease.
Importance of vaccination in fighting 
antimicrobial resistance
Today, antimicrobial resistance has grown enormously, 
and many pathogenic bacteria are resistant to multiple 
antibiotics, including such micro-organisms as Vibrio 
cholerae and S. typhi. Consequently, multi-drug resis-
tance is now one of the most alarming emerging problem 
associated with infectious diseases. On the other hand, 
vaccines can prevent infectious diseases and can yield a 
much longer-lasting control of infections. Indeed, vac-
cines can control infections over a long period of time 
without becoming obsolete. This characteristic is due to 
the fact that vaccines work prophylactically and prevent 
the start of infections, while drugs work therapeutically 
on an ongoing infection in which bacteria proliferate 
and mutate, allowing the drug to select resistant vari-
ants [93].
Regarding S. typhi, since 2001, the complete genome 
sequence of multiple drug-resistant S. typhi has been 
mapped and the genes of resistance to the antibiotics 
commonly used in the treatment of typhoid fever, es-
pecially fluoroquinolones, have been identified [94]. 
Infection caused by multiple drug-resistant strains has 
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been documented to be associated with more severe ill-
ness and higher rates of complications and death, and 
with a higher rate of prolonged asymptomatic carrier 
status [95].
In 2016 in Pakistan, an outbreak of Salmonella enterica 
(ssp. enterica serovar typhi), resistant to chlorampheni-
col, ampicillin, trimethoprim-sulfamethoxazole, fluo-
roquinolones and third-generation cephalosporins, was 
observed. More than 1000 cases were registered and lab-
oratory confirmed. The outbreak was caused by the H58 
clade, a multidrug-resistant haplotype of S. typhi, com-
mon in Asia and in some African areas. As reported by 
the authors, multi-resistant S. typhi involved a densely 
populated area of Asia where adequate sanitation, water 
and infrastructure were lacking [96].
With regard to cholera, multidrug-resistant isolates are 
emerging, particularly in Southern Asia, with resistance 
to quinolones, trimethoprim-sulfamethoxazole and tet-
racycline.
A variety of mechanisms of antimicrobial resistance 
have been identified in Vibrio cholerae, including ef-
flux pumps, chromosomal mutations and mobile ge-
netic elements such as plasmids and SXT elements. 
Antibiotics are often used in combination with re-
hydration therapy, as they are believed to relieve the 
symptoms of cholera faster than rehydration treatment 
alone, and because a shorter disease duration lessens 
the transmission of infectious Vibrio cholerae. Be-
cause antibiotics are widely used as part of the cholera 
treatment regimen, the number of pathogenic Vibrio 
cholerae strains resistant to one or more antibiotics is 
increasing [97]. To prevent the spread of resistance, 
it is crucial to limit the use of antibiotics in cholera 
patients and to implement alternative strategies and 
novel approaches in managing this disease.
The WHO does not advise the prophylactic administra-
tion of antibiotics in travelers coming from or going to 
a country affected by cholera. Indeed, routine treatment 
with antibiotics, or preventive chemoprophylaxis, has no 
effect on the spread of cholera. On the contrary, the use 
of antibiotics can have adverse effects by increasing an-
timicrobial resistance.
Although TF and cholera seem to be similar diseases, 
they display some different features in terms of geo-
graphical distribution, pathogenesis, clinical presenta-
tion, prognosis and mortality.
Regarding their geographical distribution, TF has a high 
incidence in sub-Saharan Africa, India and south-east 
Asia, while cholera has a high incidence in a few Afri-
can countries, particularly in the Horn of Africa and the 
Arabian Peninsula (Fig. 1 and Fig. 3). 
Cholera has a worse prognosis than TF during the acute 
phase of the disease, mainly owing to profuse watery di-
arrhea and vomiting, which cause massive dehydration. 
If untreated, 50% of severe cases are fatal, while proper 
treatment and fluid replacement reduce mortality to less 
than 1% [98]. Mortality is higher in children, especially 
those under 5 years of age.
International travel and migration
With modern air travel, transmissible diseases can 
spread across continents and oceans in a few days, con-
stituting a threat to public health. Indeed, it takes only 36 
hours to travel around the world by plane; a time much 
shorter than the incubation period of most infectious dis-
eases [99].
In 1950, international travelers numbered just over 25 
million, while according to estimates by the United 
Nations World Tourism Organization (UNWTO) they 
could become 1.3 billion by 2020. Over 700 million 
travelers could be exposed to an increased risk of con-
tracting infectious diseases, owing to changes in their 
habits, different weather conditions (cold, heat, humid-
ity, exposure to the sun or wind) and the consumption 
of unsafe food. Asia and the Pacific area, which account 
for 37% of the world’s international tourism expenditure 
and nearly one-fourth of global arrivals, play a vital role 
in global tourism, as both an inbound and an outbound 
market. The increase in international travel in these areas 
is due to major infrastructure and socio-economic devel-
opment [100].
Nowadays, people travel for many reasons, such as 
tourism and business. Several surveys have shown that 
a high proportion of travelers, whether tourists or busi-
nesspeople, lack adequate information on safety issues, 
such as timely vaccination and prophylactic medica-
tions. Indeed, only a small number of travelers seek ad-
vice from the Travel Medicine clinic, particularly with 
regard to vaccinations. Notably, the pre-travel planning 
of vaccinations is a complex operation that requires ad-
equate medical support and proper timing.
In a cross-sectional, multicenter study, the European 
Travel Health Advisory Board (ETHAB) used a self-ad-
ministered anonymous questionnaire to evaluate current 
travel health knowledge, attitudes and practices and to 
determine where travelers to developing countries ob-
tained travel health information, what information they 
received, and what preventive health measures they im-
plemented. The survey was conducted at several airports 
in Europe, Asia, South Africa and the United States. The 
questionnaire [101], which was distributed at the depar-
ture gate, gathered information on: personal character-
istics (age, gender, nationality, country of residence and 
profession); the journey undertaken (destination coun-
tries, type of region, purpose, duration, travel compan-
ions) and travelers’ knowledge, attitudes and practices 
(timing of travel preparation, source and timing of travel 
health information, planned food habits and restrictions, 
perceived risk of specific infectious diseases, perception 
and status of vaccinations, contents of travel health kit) 
regarding malaria and vaccine-preventable travel-related 
diseases. The results obtained from a total of 5,465 ques-
tionnaires showed that the majority of travelers (73.3%) 
had sought general information about their destination 
prior to departure, but only just over half of the respon-
dents (52.1%) had sought travel health advice. Tourists 
and people traveling for religious reasons had sought 
travel health advice more often, whereas those visiting 
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friends and relatives were less likely to do so. Hepatitis 
A was perceived as the most common infectious disease, 
followed by HIV and hepatitis B. When all participants 
were asked to score the risk of vaccine-preventable dis-
eases, between one-quarter and one-third of respondents 
stated that they did not know the risk concerning the re-
spective diseases; some 40% could not assess the risk 
at all, and 10% to 15% did not answer this question. Ig-
norance was highest with regard to rabies, TF and chol-
era [101].
Many characteristics of the journey (duration, destina-
tion, etc.) can influence decisions regarding the preven-
tive and prophylactic strategies to adopt. For example, 
the strongest and most consistent predictor of typhoid 
risk in travelers is the trip destination: 1/3,000 in travel-
ers to South Asia (high risk), 1/50,000-100,000 Sub-Sa-
haran Africa, North Africa and the Middle East or South 
America (intermediate risk) and < 1/300,000 in travelers 
to the Caribbean and Central America (low risk) [102].
A review published in 2005 confirmed that the risk to 
travelers appears to vary by geographic region visited, 
with travel to the Indian subcontinent accounting for the 
greatest risk of acquiring typhoid fever. The overall risk 
of contracting TF during travel to the Indian subconti-
nent was 18 times higher than in any other geographic 
area [103]. Many cases acquired in the Indian subconti-
nent were multidrug-resistant, as fluoroquinolone resis-
tance is on the rise in this geographical area.
A special category at higher risk of contracting TF is 
that of travelers who visit relatives (emigrants returning 
to their homeland). These subjects are less likely to have 
received pre-travel advice, less likely to adopt food and 
water precautions and, perhaps most importantly, by and 
large do not perceive their risk or undergo typhoid vac-
cination before traveling [104].
Regarding the risk of cholera, with the growth of inter-
national travel by sea and air, cases of food-borne trans-
mission of cholera have increased. Indeed, in addition to 
contaminated water, certain foodstuffs are particularly at 
risk of transmitting the disease: seafood, including fish, 
shellfish, crabs, oysters and clams, and other foods that 
can easily be contaminated during preparation in unhy-
gienic food factories or by infected food handlers [105].
Transportation systems and trade routes have greatly im-
proved and expanded worldwide, and the ease and speed 
of migration mean that cholera is still a global health 
challenge. Confirmation that cholera is still a public 
health threat associated with migration and the rapid 
movement of people is provided by the recent outbreak 
reported in Algeria. As referred by the European Cen-
tre for Disease Prevention and Control, as of 30 August 
2018, Algeria reported 74 confirmed cholera cases in six 
northern and coastal areas of the country. This was the 
first cholera outbreak reported in Algeria in more than 
20 years. Cases were reported in both rural and urban 
areas, including the capital. A water source was found 
to be contaminated with Vibrio cholerae. On the basis 
of the number of cases and the geographical extension 
of the outbreak, additional cases are expected to be re-
ported.
Conclusion
Not only are cholera and TF a severe threat to the po-
pulations of low- and middle-income countries, these 
diseases may also affect travelers to endemic areas. The 
preventive measures to be adopted in the case of travel 
to countries where these diseases are still endemic are 
well known: the adoption of safe practices and vacci-
nations [24]. It is important to stress that an effective 
strategy should be based both on vaccinations and on 
hygiene travel guidelines. It is commonly believed that 
chances of developing gastrointestinal illness will be re-
duced considerably by being counselled to “boil it, cook 
it, peel it, or forget it.” However, surveys of returning 
travellers have shown that receiving advice about food 
and drink safety appears to have no significant effect on 
rates of diarrhoea. Indeed, many travellers will commit 
a food and beverage indiscretion within 72 hours after 
arrival in a developing country, despite pre-departure 
counselling. Standard protective measures are always 
recommended such as: wash your hands thoroughly 
before eating food, avoid consuming raw foods (meat, 
fish, shellfish, vegetables and more), with the exception 
of personally peeled fruits, take well-cooked foods and 
not re-warmed; avoid milk that has not been previously 
boiled, pasteurized or sterilized, ice creams, cakes with 
cream, cream, raw egg sauces (like mayonnaise), fresh 
cheeses. Don’t buy food and drinks from street vendors 
and drink only from sealed bottles (if this is not possible, 
boil the water) [106, 107].
TF is one of the main causes of death due to food-borne 
infections, and results in the greatest loss of Disability-
Adjusted Life years (DALYs) worldwide [24]. Given 
that man is the only host of S. typhi, an effective vaccina-
tion strategy could limit the spread of disease and reduce 
its burden, especially in endemic areas [6]. Furthermore, 
the emergence of multidrug-resistant strains is becoming 
a serious problem in the clinical treatment of the disease. 
For this reason, vaccination is the main solution.
The WHO has set the goal of eliminating cholera by 
2030. To achieve this objective, it is essential to support 
the efforts of low-income countries to strengthen their 
capacities for preparedness, early detection, laboratory 
confirmation and immediate effective response to out-
breaks. In addition, travelers must be fully informed of 
the risk of disease and be vaccinated before their depar-
ture for at-risk areas. Although safe drinking water and 
advanced sanitation systems have made cholera a treat-
able and limited illness in Europe and North America, 
the emergence of new Vibrio cholerae strains, the ease 
of travel and the increased migration of possibly infected 
individuals have raised serious public health concerns.
Today, people of all ages commonly travel to developing 
countries for a variety of different reasons. The common 
objective should be to help travelers stay healthy while 
abroad, and thus also to reduce the potential importation 
of infectious diseases and its consequent implications 
for public health and society [108]. Indeed, the conse-
quences of returning from abroad with an infectious dis-
ease can extend beyond the infected individual, in that 
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they may also involve travelers’ relatives, people with 
whom they have close contact, or the wider community. 
Thus, prophylactic travel health measures do not only 
benefit individuals, but also public health [101, 109].
Initiatives to enhance the awareness of travelers should 
target all groups, including business travelers, those vis-
iting friends and relatives, and the elderly. Nowadays, 
travelling isn’t just a matter for young and adult people: 
in the last years, the number of older travelers have in-
creased. Older travelers have been encouraged by the 
greater ease of access to cheap and rapid modes of trans-
port [110]. 
Obviously, older travels are often patients, with chron-
ic diseases and other medical conditions: for example, 
lower respiratory tract infections, urinary tract infections 
and cardiovascular disease. in order to taking account of 
the special considerations for safe prescription, general 
practitioners, geriatricians and other healthcare profes-
sionals should cooperate with specialist travel medi-
cine clinics [111]. Moreover, the immunosenescence 
in elderly people is also important in travel medicine, 
because it could reduce vaccines immunogenicity and 
could increase the risk of travel-related infectious dis-
eases. For this reason older travelers, need a pre-travel 
consultation, preferably earlier than others travelers, to 
have an adequate time to respond to vaccinations, even 
if they are healthy, without immunosuppressing/im-
munocompromising conditions [112]. Additionally, the 
providers of travel health advice should continue to urge 
travelers to comply with the pertinent recommendations. 
A large and growing number of “free and independent 
travelers”, identifiable as a “consumer class”, especially 
young travelers aged 15-34 years (“millennials”), use 
online travel agencies and mobile technology to make 
faster and simpler bookings through online (and more 
affordable) tourism platforms. These changes in travel 
habits should prompt different information strategies, 
e.g. the use of social media and collaboration between 
public health organizations and the most widely used 
travel websites.
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